InVivoPlus anti-mouse CD8alpha

Catalog number: BP0004-1_100mg
Brand: Bio X Cell
Packing: 100 mg
Other sizes: 5 mg
25 mg
50 mg
Price: € 3350.00
Expected delivery time: 7 days
Quantity:

Product specifications for - InVivoPlus anti-mouse CD8alpha

Promotion: 
Promotion: The price displayed is only for academic or non-profit organizations. Please contact our helpdesk for regular prices.
Overview: 
Product group: Antibodies
Category: Primary Antibodies
Application: Flow Cytometry; ImmunoFluorescence; Other Application
Species: Mouse
Host: Rat
Clonality: Monoclonal
Isotype: IgG2a Kappa
Properties: 
Molecular weight: 150 kDa
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352203
Concentration: 2-10 mg/ml
Scientific information: 
Clone ID: 53-6.7
Related products: 
Related products: Recommended Isotype Control(s): InVivoPlus rat IgG2a isotype control (BP0089)
Recommended Dilution Buffer: InVivoPure pH 6.5 Dilution Buffer (IP0065)
Additional information: 
Synonyms: 53-6.7; BP0004-1; CD8 alpha; CD8A; p32; MAL; Leu2; CD8; T8 T-cell antigen; T-lymphocyte differentiation antigen T8/Leu-2; T-cell surface glycoprotein CD8 alpha chain; T-cell antigen Leu2; T cell co-receptor; OKT8 T-cell antigen; Leu2 T-lymphocyte antigen; CD8 antigen, alpha polypeptide (p32); CD8a molecule; BioXCell
Finisguerra V, Di conza G, Di matteo M, et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature. 2015;522(7556):349-53. Read more
Yamada DH, Elsaesser H, Lux A, et al. Suppression of Fcγ-receptor-mediated antibody effector function during persistent viral infection. Immunity. 2015;42(2):379-390. Read more
Christensen AD, Skov S, Kvist PH, Haase C. Depletion of regulatory T cells in a hapten-induced inflammation model results in prolonged and increased inflammation driven by T cells. Clin Exp Immunol. 2015;179(3):485-99. Read more
Walsh KB, Teijaro JR, Brock LG, et al. Animal model of respiratory syncytial virus: CD8+ T cells cause a cytokine storm that is chemically tractable by sphingosine-1-phosphate 1 receptor agonist therapy. J Virol. 2014;88(11):6281-93. Read more
Uddin MN, Zhang Y, Harton JA, Macnamara KC, Avram D. TNF-α-dependent hematopoiesis following Bcl11b deletion in T cells restricts metastatic melanoma. J Immunol. 2014;192(4):1946-53. Read more
Cyktor JC, Carruthers B, Beamer GL, Turner J. Clonal expansions of CD8+ T cells with IL-10 secreting capacity occur during chronic Mycobacterium tuberculosis infection. PLoS ONE. 2013;8(3):e58612. Read more
Schwager K, Hemmerle T, Aebischer D, Neri D. The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol. 2013;133(3):751-758. Read more
Hervieu A, Rébé C, Végran F, et al. Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. J Invest Dermatol. 2013;133(2):499-508. Read more
Hafalla JC, Claser C, Couper KN, et al. The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology. PLoS Pathog. 2012;8(2):e1002504. Read more
Chyou S, Benahmed F, Chen J, et al. Coordinated regulation of lymph node vascular-stromal growth first by CD11c+ cells and then by T and B cells. J Immunol. 2011;187(11):5558-67. Read more